Advertisement

Topics

Endologix, Inc. Company Profile

10:38 EDT 21st June 2018 | BioPortfolio

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.


News Articles [24 Associated News Articles listed on BioPortfolio]

Endologix names new CEO

John Onopchenko was tapped to serve as CEO of Endologix.  -More- 

Endologix, Inc. to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mah...

Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter...

Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on February 21, 2018

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quart...

Endologix Inc 2018 Q1 - Results - Earnings Call Slides

Endologix Inc 2017 Q4 - Results - Earnings Call Slides

Endologix's (ELGX) CEO John McDermott on Q4 2017 Results - Earnings Call Transcript

Endologix's (ELGX) CEO John Onopchenko on Q1 2018 Results - Earnings Call Transcript

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

The objective of this study is to assess the safety and effectiveness of the Endologix Nellix® System for the endovascular repair of infrarenal abdominal aortic aneurysms (AAA).

Companies [2 Associated Companies listed on BioPortfolio]

Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the tre...

Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of...

More Information about "Endologix, Inc." on BioPortfolio

We have published hundreds of Endologix, Inc. news stories on BioPortfolio along with dozens of Endologix, Inc. Clinical Trials and PubMed Articles about Endologix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endologix, Inc. Companies in our database. You can also find out about relevant Endologix, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stent
A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body.  A stent is placed in an artery as part of a procedure called angioplasty. &...


Corporate Database Quicklinks



Searches Linking to this Company Record